Last reviewed · How we verify

Tracrium Preservative Free (ATRACURIUM)

Hospira · FDA-approved approved Small molecule Quality 55/100

Tracrium Preservative Free (Atracurium) is a nondepolarizing neuromuscular blocker, a small molecule drug class, that targets the neuronal acetylcholine receptor subunit alpha-3. It is used for general anesthesia, muscle relaxation, and endotracheal intubation. Originally developed, it is now owned by Hospira and has been FDA approved since 1983. Tracrium Preservative Free is available as a generic medication with 11 manufacturers and is off-patent. Key safety considerations include its short half-life of 0.31 hours.

At a glance

Generic nameATRACURIUM
SponsorHospira
Drug classNondepolarizing Neuromuscular Blocker
TargetNeuronal acetylcholine receptor subunit alpha-3
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval1983

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: